GlassScriptPhysician profile
Emily Evans
NPI 1114660248
$711.59
in general payments reported to CMS, 2019-2025
12 companies · $579 in 2025
The $579 reported for 2025 was more than what 81% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $22.74 · 2024: $110 · 2025: $579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $712.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $711.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $154.09 | 2024-2025 | Zurzuvae |
| Astellas Pharma US INC | $123.98 | 2023-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $120.24 | 2024-2025 | |
| Mayne Pharma Commercial LLC | $78.66 | 2025 | |
| Organon LLC | $59.48 | 2024-2025 | Nexplanon |
| Sumitomo Pharma America, INC. | $42.45 | 2025 | Myfembree |
| Optumhealth Care Solutions, LLC | $39.45 | 2025 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Pfizer INC. | $23.12 | 2025 | |
| Supernus Pharmaceuticals, INC. | $20.83 | 2025 | Qelbree |
| Millicent US INC | $18.39 | 2025 | Femlyv |
| Exeltis, USA INC. | $15.70 | 2024 | Slynd |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.20 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.